Health Care [ 4/12 ] | Pharmaceuticals [ 14/72 ]
NASDAQ | Common Stock
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States.
The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.
OptiNose, Inc. has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail; and Orexia Therapeutics to develop, manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation.
The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jun 6, 24 | -0.12 Increased by +26.53% | -0.11 Decreased by -13.55% |
| Mar 7, 24 | -0.09 Increased by +47.06% | -0.09 |
| Nov 9, 23 | -0.08 Increased by +55.56% | -0.09 Increased by +11.11% |
| Aug 10, 23 | 0.02 Increased by +108.70% | -0.11 Increased by +118.18% |
| May 11, 23 | -0.17 Increased by +45.16% | -0.14 Decreased by -21.43% |
| Mar 7, 23 | -0.17 Increased by +26.09% | -0.17 |
| Nov 10, 22 | -0.18 Increased by +43.75% | -0.18 |
| Aug 11, 22 | -0.23 Increased by +47.73% | -0.24 Increased by +4.17% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 19.82 M Decreased by -1.27% | -9.29 M Increased by +37.83% | Decreased by -46.88% Increased by +37.03% |
| Jun 30, 23 | 19.45 M Decreased by -5.48% | 2.63 M Increased by +113.54% | Increased by +13.50% Increased by +114.32% |
| Mar 31, 23 | 11.85 M Decreased by -19.74% | -18.65 M Increased by +26.36% | Decreased by -157.47% Increased by +8.25% |
| Dec 31, 22 | 20.86 M Decreased by -7.34% | -17.33 M Decreased by -10.94% | Decreased by -83.10% Decreased by -19.73% |
| Sep 30, 22 | 20.08 M Decreased by -8.01% | -14.95 M Increased by +12.67% | Decreased by -74.45% Increased by +5.06% |
| Jun 30, 22 | 20.58 M Increased by +12.12% | -19.40 M Increased by +17.46% | Decreased by -94.25% Increased by +26.38% |
| Mar 31, 22 | 14.76 M Increased by +23.41% | -25.33 M Increased by +2.77% | Decreased by -171.63% Increased by +21.21% |
| Dec 31, 21 | 22.51 M Increased by +37.69% | -15.62 M Increased by +34.53% | Decreased by -69.41% Increased by +52.46% |